

February 19, 2026

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated February 19, 2026, titled “**Closure of USFDA inspection at Zydus’ Injectable plant at Ahmedabad**”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **Zydus Lifesciences Limited**

Dhaval N. Soni

Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above



Closure of USFDA inspection at Zydus' Injectable plant at Ahmedabad

Ahmedabad, India, 19 February, 2026

We wish to inform that the US, Food and Drug Administration (USFDA) conducted Pre Approval Inspection (PAI) for Injectable Medical Devices at the company's Unit 9 facility located at Zydus Biotech Park, Changodar, Ahmedabad. The inspection was conducted from 16th to 19th February, 2026.

The inspection closed with NIL observations

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878